0001193125-13-294353.txt : 20130718 0001193125-13-294353.hdr.sgml : 20130718 20130718163054 ACCESSION NUMBER: 0001193125-13-294353 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20130718 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130718 DATE AS OF CHANGE: 20130718 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTUITIVE SURGICAL INC CENTRAL INDEX KEY: 0001035267 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 770416458 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30713 FILM NUMBER: 13975137 BUSINESS ADDRESS: STREET 1: 950 KIFER ROAD CITY: SUNNYVALE STATE: CA ZIP: 94086 BUSINESS PHONE: 4085232100 MAIL ADDRESS: STREET 1: 950 KIFER ROAD CITY: SUNNYVALE STATE: CA ZIP: 94086 8-K 1 d570778d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 18, 2013

 

 

INTUITIVE SURGICAL, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-30713   77-0416458

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

1266 Kifer Road

Sunnyvale, California 94086

(Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: (408) 523-2100

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 2.02.  Results of Operations and Financial Condition.

On July 18, 2013, Intuitive Surgical, Inc. (“Intuitive”) issued a press release announcing its financial results for the quarter ended June 30, 2013. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of Intuitive under the Securities Act of 1933 or the Exchange Act.

 

Item 9.01.  Financial Statements and Exhibits.

d) Exhibits.

The following exhibit is furnished with this report on Form 8-K:

 

99.1    Press release issued by Intuitive Surgical, Inc., dated July 18, 2013.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INTUITIVE SURGICAL, INC.
Date: July 18, 2013   By  

 /s/ Marshall L. Mohr

         Name: Marshall L. Mohr
         Title: Senior Vice President and Chief Financial Officer


EXHIBIT INDEX

 

Exhibit No.    Description
99.1    Press Release issued by Intuitive Surgical, Inc., dated July 18, 2013.
EX-99.1 2 d570778dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

 

Contact: Investor Relations

(408) 523-2161    

INTUITIVE SURGICAL ANNOUNCES SECOND QUARTER EARNINGS

SUNNYVALE, CALIF. July 18, 2013 – Intuitive Surgical, Inc. (NASDAQ: ISRG), the industry leader in robotic-assisted surgery, today reported second quarter of 2013 revenue, consistent with its July 8th release, of $579 million, up approximately 8% compared with $537 million for the second quarter of 2012.

Second quarter of 2013 instruments and accessories revenue increased 18% to $265 million from $224 million in the second quarter of 2012. The growth in instruments and accessories revenue is the result of growth in da Vinci® surgical procedures and increased utilization of new products. da Vinci surgical procedures grew approximately 18% in the second quarter of 2013 compared to the second quarter of 2012, driven primarily by growth in general surgery, U.S. gynecology and international urology procedures, partially offset by a decline in U.S. prostatectomy procedures.

Second quarter of 2013 systems revenue was $216 million, a decrease of 6%, compared with $229 million during the second quarter of 2012. During the second quarter of 2013, we sold 143 da Vinci Surgical Systems compared with sales of 150 systems during the same period last year. Second quarter of 2013 service revenue increased 18% to $98 million from $83 million during the second quarter of 2012, reflecting growth in the installed base of da Vinci Surgical Systems.

Second quarter of 2013 operating income decreased to $219 million from $225 million in the second quarter of 2012. Operating results for the second quarter of 2013 included $39 million of non-cash stock-based compensation expense compared with $33 million for the second quarter of 2012.

Intuitive Surgical’s income tax rate for the second quarter of 2013 was 28.6% compared with 32.4% for the second quarter of 2012.

Second quarter of 2013 net income was $159 million, or $3.90 per diluted share, compared with $155 million, or $3.75 per diluted share, for the second quarter of 2012.

Intuitive Surgical ended the second quarter of 2013 with $3.0 billion in cash, cash equivalents and investments, reflecting a decrease of $89 million during the quarter. $270 million in cash was used to repurchase approximately 546,000 shares of Intuitive Surgical’s common stock in the second quarter of 2013 at an average price of $494 per share.


Intuitive Surgical will also announce these results at a conference call today at 1:30 pm PDT. The dial-in numbers for the call are (800) 230-1092 for participants located in the United States and (612) 288-0337 for participants located outside the United States. The host is Dr. Gary Guthart. To access financial information that will be discussed on the call, please visit Intuitive Surgical’s website at www.intuitivesurgical.com.

About Intuitive Surgical, Inc.

Intuitive Surgical, Inc. (Nasdaq: ISRG), headquartered in Sunnyvale, Calif., is the global leader in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops, manufactures and markets the da Vinci Surgical System. Intuitive Surgical’s mission is to extend the benefits of minimally invasive surgery to those patients who can and should benefit from it.

About the da Vinci Surgical System

The da Vinci Surgical System is a surgical platform designed to enable complex surgery using a minimally invasive approach. The da Vinci Surgical System consists of an ergonomic surgeon console or consoles, a patient-side cart with three or four interactive arms, a high-performance vision system and proprietary EndoWrist® instruments. Powered by state-of-the-art technology, the da Vinci Surgical System is designed to scale, filter and seamlessly translate the surgeon’s hand movements into more precise movements of the EndoWrist instruments. The net result is an intuitive interface with improved surgical capabilities. By providing surgeons with superior visualization, enhanced dexterity, greater precision and ergonomic comfort, the da Vinci Surgical System makes it possible for skilled surgeons to perform more minimally invasive procedures involving complex dissection or reconstruction. For more information about clinical evidence related to da Vinci Surgery, please visit www.intuitivesurgical.com/company/clinical-evidence/

da Vinci® and EndoWrist® are trademarks of Intuitive Surgical, Inc.

# # #

This press release contains forward-looking statements. These forward-looking statements are necessarily estimates reflecting the best judgment of our management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including the following: the impact of global and regional economic and credit market conditions on health care spending; health care reform legislation in the United States and its impact on hospital spending, reimbursement and fees which will be levied on certain medical device revenues; decreases in hospital admissions and actions by payers to limit or manage surgical procedures; timing and success of product development and market acceptance of developed


products; procedure counts; regulatory approvals, clearances and restrictions; guidelines and recommendations in the health care and patient communities; intellectual property positions and litigation; competition in the medical device industry and in the specific markets of surgery in which we operate; unanticipated manufacturing disruptions or the inability to meet demand for products; the results of legal proceedings to which we are or may become a party; product liability and other litigation claims; adverse publicity regarding the Company and the safety of our products and adequacy of training; our ability to expand into foreign markets; and other risk factors under the heading “Risk Factors”’ in our report on Form 10-K for the year ended December 31, 2012, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Statements concerning forecasts, revenue growth, procedure growth, future financial results and statements using Words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “would,” “targeted” and similar words and expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.


INTUITIVE SURGICAL, INC.

UNAUDITED QUARTERLY CONSOLIDATED STATEMENTS OF INCOME

(IN MILLIONS, EXCEPT PER SHARE DATA)

 

     Three months ended  
     June 30,      March 31,      June 30,  
     2013      2013      2012  

Revenue:

        

Instruments and accessories

   $ 264.5       $ 261.1       $ 223.7   

Systems

     215.9         255.9         229.4   

Services

     98.1         94.4         83.4   
  

 

 

    

 

 

    

 

 

 

Total revenue

     578.5         611.4         536.5   

Cost of revenue:

        

Product

     140.9         146.3         122.9   

Service

     32.4         30.8         27.2   
  

 

 

    

 

 

    

 

 

 

Total cost of revenue (1)

     173.3         177.1         150.1   

Gross profit

     405.2         434.3         386.4   

Operating expenses:

        

Selling, general, and administrative

     145.5         141.5         120.9   

Research and development

     41.2         41.6         40.2   
  

 

 

    

 

 

    

 

 

 

Total operating expenses (1)

     186.7         183.1         161.1   

Income from operations (2)

     218.5         251.2         225.3   

Interest and other income (expense), net

     4.3         4.3         4.0   
  

 

 

    

 

 

    

 

 

 

Income before taxes

     222.8         255.5         229.3   

Income tax expense

     63.7         66.6         74.4   
  

 

 

    

 

 

    

 

 

 

Net income

   $ 159.1       $ 188.9       $ 154.9   
  

 

 

    

 

 

    

 

 

 

Net income per share:

        

Basic

   $ 3.99       $ 4.69       $ 3.88   
  

 

 

    

 

 

    

 

 

 

Diluted

   $ 3.90       $ 4.56       $ 3.75   
  

 

 

    

 

 

    

 

 

 

Shares used in computing net income per share:

        

Basic

     39.9         40.3         39.9   
  

 

 

    

 

 

    

 

 

 

Diluted

     40.8         41.4         41.3   
  

 

 

    

 

 

    

 

 

 

(1)   Includes share-based compensation expense as follows:

        

Total cost of revenue

   $ 7.1       $ 6.8       $ 5.8   

Total operating expenses

   $ 31.6       $ 31.4       $ 27.5   

(2)   Includes amortization of purchased intangibles as follows:

        

Income from operations

   $ 5.7       $ 5.6       $ 6.1   


INTUITIVE SURGICAL, INC.

UNAUDITED SIX MONTHS ENDED CONSOLIDATED STATEMENTS OF INCOME

(IN MILLIONS, EXCEPT PER SHARE DATA)

 

     Six months ended  
     June 30,  
     2013      2012  

Revenue:

     

Instruments and accessories

   $ 525.6       $ 431.5   

Systems

     471.8         436.0   

Services

     192.5         164.2   
  

 

 

    

 

 

 

Total revenue

     1,189.9         1,031.7   

Cost of revenue:

     

Product

     287.2         234.6   

Service

     63.2         54.8   
  

 

 

    

 

 

 

Total cost of revenue (1)

     350.4         289.4   

Gross profit

     839.5         742.3   

Operating expenses:

     

Selling, general, and administrative

     287.0         245.1   

Research and development

     82.8         78.6   
  

 

 

    

 

 

 

Total operating expenses (1)

     369.8         323.7   

Income from operations (2)

     469.7         418.6   

Interest and other income (expense), net

     8.6         7.8   
  

 

 

    

 

 

 

Income before taxes

     478.3         426.4   

Income tax expense

     130.3         128.0   
  

 

 

    

 

 

 

Net income

   $ 348.0       $ 298.4   
  

 

 

    

 

 

 

Net income per share:

     

Basic

   $ 8.68       $ 7.52   
  

 

 

    

 

 

 

Diluted

   $ 8.47       $ 7.26   
  

 

 

    

 

 

 

Shares used in computing net income per share:

     

Basic

     40.1         39.7   
  

 

 

    

 

 

 

Diluted

     41.1         41.1   
  

 

 

    

 

 

 

(1)   Includes share-based compensation expense as follows:

     

Total cost of revenue

   $ 13.9       $ 11.7   

Total operating expenses

   $ 63.0       $ 56.0   

(2)   Includes amortization of purchased intangibles as follows:

     

Income from operations

   $ 11.3       $ 12.0   


INTUITIVE SURGICAL, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(IN MILLIONS)

 

     June 30, 2013      December 31, 2012  

Cash, cash equivalents and investments

   $ 3,027.2       $ 2,920.5   

Accounts receivable, net

     358.6         370.3   

Inventories

     169.3         121.5   

Property, plant and equipment, net

     267.6         241.8   

Goodwill

     137.4         138.1   

Deferred tax assets

     115.7         96.3   

Other assets

     125.5         170.7   
  

 

 

    

 

 

 

Total assets

   $ 4,201.3       $ 4,059.2   
  

 

 

    

 

 

 

Accounts payable and other accrued liabilities

   $ 284.3       $ 292.7   

Deferred revenue

     198.2         186.4   
  

 

 

    

 

 

 

Total liabilities

     482.5         479.1   

Stockholders’ equity

     3,718.8         3,580.1   
  

 

 

    

 

 

 

Total liabilities and stockholders’ equity

   $ 4,201.3       $ 4,059.2